Traumakine to be a part of WHO’s Solidarity trial
Faron Pharmaceuticals Oy("Faron" or the "Company") Traumakine to be a part of WHO's Solidarity trial investigating potential COVID-19 treatments Company announcement, 27 April 2020 at 9.00 AM (EEST)Inside information TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that the Company will donate supplies of its investigational intravenous (IV) interferon (IFN) beta-1a for 2,000 patients in the World Health Organization's (WHO) Solidarity trial investigating potential COVID-19 treatments.